伊诺加群
| 中文名称 | 伊诺加群 |
|---|---|
| 中文同义词 | 伊诺加群;化合物 T11659;INOGATRAN (H-314-27) |
| 英文名称 | inogatran |
| 英文同义词 | inogatran;Glycine, N-[(1R)-2-[(2S)-2-[[[3-[(aminoiminomethyl)amino]propyl]amino]carbonyl]-1-piperidinyl]-1-(cyclohexylmethyl)-2-oxoethyl]-;H-314-27;Inogatran (H-314-27) |
| CAS号 | 155415-08-0 |
| 分子式 | C21H38N6O4 |
| 分子量 | 438.56 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 155415-08-0.mol |
| 结构式 |  |
伊诺加群 性质
| 密度 | 1.36±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | Store at -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 酸度系数(pKa) | 2.16±0.10(Predicted) |
Inogatran (H-314-27) 是一种合成的 thrombin 抑制剂，主要用于预防动脉和静脉血栓性疾病。
Inogatran (H-314-27; 0.075, 0.25, 0.75 mg/kg, i.v.) results in dose-dependent increases in activated partial thromboplastin time (aPTT), thrombin time (TT), and prothrombin time (PT) in a canine electrolytic injury model of venous thrombosis.
Inogatran dose-dependently inhibits thrombus formation, which is measured as an increase in time to occlusion (TTO) and a decrease in thrombus weight. Inogatran also improves vena caval blood flow and reduces the overall incidence of thrombotic occlusion in a rat model.